» Articles » PMID: 12740298

Pulmonary Embolism in Idiopathic Pulmonary Fibrosis Transplant Recipients

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2003 May 13
PMID 12740298
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The objectives of the study were the assessment of the incidence of pulmonary embolism (PE) in lung transplant recipients. We performed a retrospective review of the medical records in a tertiary center lung transplant program. A total of 72 lung transplants were performed. There were seven symptomatic PE events diagnosed among six patients (group 1). All PE events were in the subgroup of patients with idiopathic pulmonary fibrosis (IPF) [6 of 23 patients (27%) vs 0 among all other patients (0%); p < 0.001]. All patients were out of the hospital, not receiving oxygen therapy, and were ambulatory at the time of the event. The median time to occurrence of the PE was 175 days posttransplant (range, 26 to 541 days). All patients who developed PEs were men. The group of IPF patients with no PEs was evenly split between genders (group 2; p < 0.009). PE patients required a longer posttransplant hospitalization (mean [+/- SD], 18.5 +/- 3.9 vs 13.5 +/- 4 days, respectively; p < 0.018). Aside from this, there was no apparent difference in patient functional status between the two groups. PEs appear to be relatively common in IPF lung transplant recipients. This should be considered in the differential diagnosis of any such patient who presents with dyspnea or hypoxia posttransplant. Patients do not appear to have been predisposed to their embolic events through lack of activity or prolonged hospital stays.

Citing Articles

Survival in Patients With Evidence of Pulmonary Thromboembolism on Ventilation-Perfusion SPECT 12 Weeks After Double Lung Transplantation: A Retrospective Cohort Study.

Mohammad M, Kristensen A, Hartmann J, Wareham N, Buttar S, Greve A Clin Transplant. 2025; 39(2):e70103.

PMID: 39927856 PMC: 11809467. DOI: 10.1111/ctr.70103.


Pulmonary Embolism Following Lung Transplantation: Prevention and Management.

Mohammadi D, Keshavamurthy S Int J Angiol. 2024; 33(2):123-127.

PMID: 38846988 PMC: 11152625. DOI: 10.1055/s-0044-1786859.


Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.

Shlobin O, Shen E, Wort S, Piccari L, Scandurra J, Hassoun P Pulm Circ. 2024; 14(1):e12310.

PMID: 38205098 PMC: 10777777. DOI: 10.1002/pul2.12310.


Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary....

Piccari L, Allwood B, Antoniou K, Chung J, Hassoun P, Nikkho S Pulm Circ. 2023; 13(2):e12213.

PMID: 37025209 PMC: 10071306. DOI: 10.1002/pul2.12213.


Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management.

Luppi F, Kalluri M, Faverio P, Kreuter M, Ferrara G Respir Res. 2021; 22(1):109.

PMID: 33865386 PMC: 8052779. DOI: 10.1186/s12931-021-01711-1.